- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT00075478
Total-Body Irradiation With or Without Fludarabine Phosphate Followed By Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer
A Multi-center Phase III Study Comparing Nonmyeloablative Conditioning With TBI Versus Fludarabine/TBI for HLA-matched Related Hematopoietic Cell Transplantation for Treatment of Hematologic Malignancies
Aperçu de l'étude
Statut
Les conditions
- Tumeur des cellules hématopoïétiques et lymphoïdes
- Lymphome diffus à grandes cellules B
- Lymphome hodgkinien réfractaire
- Macroglobulinémie de Waldenström
- Lymphome à cellules du manteau
- Myélome plasmocytaire
- Leucémie lymphoïde chronique réfractaire
- Tumeur myélodysplasique/myéloproliférative
- Leucémie myéloïde chronique en phase chronique, BCR-ABL1 Positif
- Lymphome non hodgkinien agressif
- Lymphome non hodgkinien indolent
- Leucémie myéloïde aiguë en rémission
- Leucémie aiguë lymphoblastique en rémission
Description détaillée
PRIMARY OBJECTIVES:
I. To compare overall survival at 3 years after conditioning with 200 cGy TBI alone vs. fludarabine (fludarabine phosphate)/200 cGy TBI in heavily pretreated patients with hematologic malignancies at low/moderate risk for graft rejection.
SECONDARY OBJECTIVES:
I. To compare the non-relapse mortality 1-year after conditioning in patients who received TBI alone vs. fludarabine/TBI.
II. To compare the incidences of graft rejection in patients who received TBI alone vs. fludarabine/TBI.
III. To compare the incidences of grades II-IV acute graft-versus-host disease (GVHD) and chronic extensive GVHD.
IV. To compare rates of disease progression and/or relapse-related mortality.
V. To compare the immune reconstitution and the risks of infections.
OUTLINE:
NONMYELOABLATIVE CONDITIONING REGIMEN: Patients are randomized to 1 of 2 treatment arms.
ARM I: Patients receive fludarabine phosphate intravenously (IV) on days -4 to -2. Patients then undergo low-dose TBI on day 0.
ARM II: Patients undergo low-dose TBI on day 0.
ALLOGENEIC PERIPHERAL BLOOD STEM CELL TRANSPLANTATION (PBSCT): After TBI, patients undergo PBSCT on day 0.
IMMUNOSUPPRESSION: Patients receive cyclosporine orally (PO) twice daily (BID) on days -3 to 56 in the absence of GVHD. Patients with no evidence of GVHD at day 56 begin a cyclosporine taper and continue the taper until day 180. Patients with evidence of disease progression and no evidence of GVHD prior to day 56 receive tapered doses of cyclosporine for 2 weeks. Patients also receive mycophenolate mofetil (MMF) PO BID on days 0-28 in the absence of GVHD. If treatment for GVHD is required before day 28, MMF is continued until a steroid taper begins.
Patients are followed up periodically for 1.5 years and then annually for 5 years post-transplantation.
Type d'étude
Inscription (Réel)
Phase
- Phase 3
Contacts et emplacements
Lieux d'étude
-
-
-
Koln, Allemagne, 50924
- Medizinische Univ Klinik Koln
-
Leipzig, Allemagne, D-04103
- Universitaet Leipzig
-
Tuebingen, Allemagne, D-72076
- University of Tuebingen-Germany
-
-
-
-
-
Torino, Italie, 10126
- University of Torino
-
-
-
-
Oregon
-
Medford, Oregon, États-Unis, 97504
- OHSU Cancer Institute-Southern Region
-
-
Utah
-
Salt Lake City, Utah, États-Unis, 84112
- Huntsman Cancer Institute/University of Utah
-
Salt Lake City, Utah, États-Unis, 84143
- LDS Hospital
-
-
Washington
-
Seattle, Washington, États-Unis, 98109
- Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
-
Seattle, Washington, États-Unis, 98101
- VA Puget Sound Health Care System
-
-
Wisconsin
-
Milwaukee, Wisconsin, États-Unis, 53226
- Froedtert and the Medical College of Wisconsin
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Patients must be not eligible for conventional allogeneic hematopoietic cell transplantation (HCT) and must have disease expected to be stable for at least 100 days without chemotherapy
- An autograft immediately prior (less than 6 months) to nonmyeloablative HCT (tandem approach) is not permitted
- Patients with hematologic malignancies treatable with HCT or with a B cell malignancy except those curable with autologous transplant will be included
- Aggressive non-Hodgkin lymphomas (NHLs) and other histologies such as diffuse large B cell NHL: patients are eligible IF they are not eligible for autologous hematopoietic stem cell transplantation (HSCT), not eligible for conventional myeloablative HSCT, or have failed an autologous HSCT
- Low grade NHL with < 6 month duration of complete remission (CR) between courses of conventional therapy
- Mantle cell NHL; may be treated in first CR
Chronic lymphocytic leukemia (CLL) must have either:
- Failed to meet National Cancer Institute (NCI) Working Group criteria for complete or partial response after therapy with a regimen containing fludarabine phosphate (FLU) (or another nucleoside analog, e.g. cladribine [2-CDA], pentostatin) or experience disease relapse within 12 months after completing therapy with a regimen containing FLU (or another nucleoside analog)
- Failed FLU-cyclophosphamide [CY]-rituximab (FCR) combination chemotherapy at any time point
- Have "17p deletion" cytogenetic abnormality; patients should have received induction chemotherapy but could be transplanted in 1st CR
- Or patients with a diagnosis of CLL (or small lymphocytic lymphoma) or diagnosis of CLL that progresses to prolymphocytic leukemia (PLL), or T-cell CLL or PLL
- Hodgkin lymphoma (HL): must have received and failed frontline therapy; patients must have failed or were not eligible for autologous transplant
- Multiple myeloma (MM): must have chemosensitive disease after failed autografting (an autografting immediately prior [within 6 months] to nonmyeloablative HCT [tandem approach] is not permitted)
- Acute myeloid leukemia (AML): must have < 5% marrow blasts at the time of transplant and be beyond first CR
- Acute lymphocytic leukemia (ALL): must have < 5% marrow blasts at the time of transplant and be beyond first CR
- Chronic myelogenous leukemia (CML): patients will be accepted in chronic phase (CP) beyond CP1 if they have received previous myelosuppressive chemotherapy or HCT, < 5% marrow blasts at time of transplant
- Myelodysplastic syndromes (MDS)/myeloproliferative disorders (MPD): must have received previous myelosuppressive chemotherapy or HCT, < 5% marrow blasts at time of transplant
- Waldenstroms Macroglobulinemia: must have failed 2 courses of therapy
- Patients will not be allowed to receive myelosuppressive chemotherapy for three weeks prior to conditioning
- Patients < 12 years old must be approved by both the participating institutions' patient review committee such as the Patient Care Conference (PCC) at the Fred Hutchinson Cancer Research Center (FHCRC) and the FHCRC principal investigator
- Patients who refused to be treated on a conventional HCT protocol; for this inclusion criterion, transplants must be approved by both the participating institution's patient review committee such as the Patient Care Conference (PCC) at the FHCRC and the FHCRC principal investigator
- Patients with human leukocyte antigen (HLA)-matched related donors
- DONOR: Related donor who is HLA genotypically identical at least at one haplotype and may be phenotypically or genotypically identical at the allele level at HLA-A, -B, -C, -DRB1, and -DQB1
- DONOR: Donor must consent to filgrastim (G-CSF) administration and leukapheresis
- DONOR: Donor must have adequate veins for leukapheresis or agree to placement of central venous catheter (femoral, subclavian)
- DONOR: For females of child bearing age, serum pregnancy qualitative (PGSTAT) within 72 hours prior to initial dose of filgrastim (G-CSF); results must be available prior to filgrastim
Exclusion Criteria:
- Eligible for a high priority curative autologous transplant
- Patients with rapidly progressive, aggressive NHL unless in minimal disease state
- Patients with chronic myelomonocytic leukemia
- Presence of circulating leukemic blasts (in the peripheral blood) detected by standard pathology for patients with AML, ALL or CML
- Life expectancy severely limited by diseases other than malignancy
- Any current central nervous system (CNS) involvement with disease refractory to intrathecal chemotherapy
- Fertile men or women unwilling to use contraceptives during and for up to 12 months post treatment
- Female patients who are pregnant or breastfeeding
- Human immunodeficiency virus (HIV) positive patients
- Patients with active non-hematological malignancies (except localized non-melanoma skin malignancies)
- Patients with a history of non-hematologic malignancies (except non-melanoma skin cancers) currently in a complete remission, who are less than 5 years from the time of complete remission, and have a > 20% risk of disease recurrence
- Fungal infections with radiological progression after receipt of amphotericin formulation or mold-active azoles for greater than 1 month
- Patients with active bacterial or fungal infections unresponsive to medical therapy
- Karnofsky score < 50 for adult patients
- Lansky-Play performance score < 50 for pediatric patients
- The addition of cytotoxic agents for "cytoreduction" with the exception of tyrosine kinase inhibitors (imatinib mesylate), cytokine therapy, hydroxyurea, low dose cytarabine, chlorambucil, or rituxan will not be allowed within three weeks of the initiation of conditioning
Patients with the following organ dysfunction:
- Symptomatic coronary artery disease or ejection fraction < 35% or other cardiac failure requiring therapy (required for patients with history of cardiac disease or anthracycline use); ejection fraction is required if age > 50 years or there is a history of anthracycline exposure or history of cardiac disease
- Poorly controlled hypertension on multiple antihypertensives
- Pulmonary: diffusion capacity of carbon monoxide (DLCO) < 30%, total lung capacity (TLC) < 30%, forced expiratory volume in one second (FEV1) < 30% and/or receiving supplementary continuous oxygen; the FHCRC study principal investigator (PI) must approve enrollment of all patients with pulmonary nodules
- Liver function abnormalities: patients with clinical or laboratory evidence of liver disease would be evaluated for the cause of liver disease, its clinical severity in terms of liver function, bridging fibrosis, and the degree of portal hypertension; patients will be excluded if they are found to have fulminant liver failure, cirrhosis of the liver with evidence of portal hypertension, alcoholic hepatitis, esophageal varices, a history of bleeding esophageal varices, hepatic encephalopathy, uncorrectable hepatic synthetic dysfunction evinced by prolongation of the prothrombin time, ascites related to portal hypertension, bacterial or fungal liver abscess, biliary obstruction, chronic viral hepatitis with total serum bilirubin > 3 mg/dL, and symptomatic biliary disease
- DONOR: Age less than 12 years
- DONOR: Identical twin
- DONOR: Pregnancy
- DONOR: Infection with HIV
- DONOR: Known allergy to filgrastim
- DONOR: Current serious systemic illness that would result in increased risk for filgrastim mobilization and harvest of PBSC
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
---|---|
Expérimental: Arm I (chemotherapy, TBI, transplant, GVHD prophylaxis)
Patients receive fludarabine phosphate IV on days -4 to -2.
Patients then undergo low-dose TBI on day 0. After TBI, patients undergo PBSCT on day 0. Patients receive cyclosporine PO BID on days -3 to 56 in the absence of GVHD.
Patients with no evidence of GVHD at day 56 begin a cyclosporine taper and continue the taper until day 180.
Patients with evidence of disease progression and no evidence of GVHD prior to day 56 receive tapered doses of cyclosporine for 2 weeks.
Patients also receive MMF PO BID on days 0-28 in the absence of GVHD.
If treatment for GVHD is required before day 28, MMF is continued until a steroid taper begins.
|
Bon de commande donné
Autres noms:
Étant donné IV
Autres noms:
Bon de commande donné
Autres noms:
Subir une greffe
Autres noms:
Undergo TBI
Autres noms:
|
Comparateur actif: Arm II (TBI, transplant, GVHD prophylaxis)
Patients undergo low-dose TBI on day 0. After TBI, patients undergo PBSCT on day 0. Patients receive cyclosporine PO BID on days -3 to 56 in the absence of GVHD.
Patients with no evidence of GVHD at day 56 begin a cyclosporine taper and continue the taper until day 180.
Patients with evidence of disease progression and no evidence of GVHD prior to day 56 receive tapered doses of cyclosporine for 2 weeks.
Patients also receive MMF PO BID on days 0-28 in the absence of GVHD.
If treatment for GVHD is required before day 28, MMF is continued until a steroid taper begins.
|
Bon de commande donné
Autres noms:
Bon de commande donné
Autres noms:
Subir une greffe
Autres noms:
Undergo TBI
Autres noms:
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
Overall Survival
Délai: 3 years after transplant
|
Percentage of patients surviving as estimated by Kaplan-Meier.
|
3 years after transplant
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
Incidence of Non-relapse Mortality
Délai: 3 years after transplant
|
Percentage of NRM as estimated by cumulative incidence methods with competing risks
|
3 years after transplant
|
Incidence of Relapse/Progression
Délai: 3 years after transplant
|
Percentage of relapse estimated by cumulative incidence methods
|
3 years after transplant
|
Incidence of Relapse-related Mortality
Délai: 3 years after transplant
|
Percentage of death following relapse/progression, estimated by cumulative incidence methods
|
3 years after transplant
|
Incidence of Grades II-IV Acute GVHD
Délai: 120 days after transplant
|
Percentage patients with grades II-IV GHVD, estimated by cumulative incidence methods
|
120 days after transplant
|
Incidence of Chronic Extensive GVHD
Délai: 3 years after transplant
|
Percentage patients with chronic extensive GVHD, estimated by cumulative incidence methods
|
3 years after transplant
|
Incidence of Graft Rejection
Délai: 1 year after transplant
|
Donor CD3 chimerism less than 5%
|
1 year after transplant
|
Progression-free Survival
Délai: 3 years after transplant
|
Percentage of patients with progression-free survival, estimated by cumulative incidence methods
|
3 years after transplant
|
Collaborateurs et enquêteurs
Publications et liens utiles
Publications générales
- Cooper JP, Storer BE, Granot N, Gyurkocza B, Sorror ML, Chauncey TR, Shizuru J, Franke GN, Maris MB, Boyer M, Bruno B, Sahebi F, Langston AA, Hari P, Agura ED, Lykke Petersen S, Maziarz RT, Bethge W, Asch J, Gutman JA, Olesen G, Yeager AM, Hubel K, Hogan WJ, Maloney DG, Mielcarek M, Martin PJ, Flowers MED, Georges GE, Woolfrey AE, Deeg JH, Scott BL, McDonald GB, Storb R, Sandmaier BM. Allogeneic hematopoietic cell transplantation with non-myeloablative conditioning for patients with hematologic malignancies: Improved outcomes over two decades. Haematologica. 2021 Jun 1;106(6):1599-1607. doi: 10.3324/haematol.2020.248187.
- Kornblit B, Maloney DG, Storb R, Storek J, Hari P, Vucinic V, Maziarz RT, Chauncey TR, Pulsipher MA, Bruno B, Petersen FB, Bethge WA, Hubel K, Bouvier ME, Fukuda T, Storer BE, Sandmaier BM. Fludarabine and 2-Gy TBI is superior to 2 Gy TBI as conditioning for HLA-matched related hematopoietic cell transplantation: a phase III randomized trial. Biol Blood Marrow Transplant. 2013 Sep;19(9):1340-7. doi: 10.1016/j.bbmt.2013.06.002. Epub 2013 Jun 11.
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimation)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
- Maladies cardiovasculaires
- Maladies vasculaires
- Maladies du système immunitaire
- Tumeurs par type histologique
- Troubles lymphoprolifératifs
- Maladies lymphatiques
- Troubles immunoprolifératifs
- Maladies de la moelle osseuse
- Maladies hématologiques
- Troubles hémorragiques
- Troubles hémostatiques
- Paraprotéinémies
- Troubles des protéines sanguines
- Tumeurs, plasmocyte
- Leucémie, Lymphoïde
- Leucémie, cellule B
- Lymphome à cellules B
- Tumeurs
- Lymphome
- Lymphome diffus à grandes cellules B
- Myélome multiple
- Leucémie
- Leucémie myéloïde
- Lymphome non hodgkinien
- Lymphome à cellules du manteau
- Leucémie-lymphome lymphoblastique à cellules précurseurs
- Macroglobulinémie de Waldenström
- Leucémie lymphocytaire chronique à cellules B
- Leucémie, myéloïde, chronique, BCR-ABL positif
- Leucémie, myéloïde, phase chronique
- Troubles myéloprolifératifs
- Maladies myélodysplasiques-myéloprolifératives
- Effets physiologiques des médicaments
- Mécanismes moléculaires de l'action pharmacologique
- Agents anti-infectieux
- Inhibiteurs d'enzymes
- Agents antirhumatismaux
- Antimétabolites, Antinéoplasique
- Antimétabolites
- Agents antinéoplasiques
- Agents immunosuppresseurs
- Facteurs immunologiques
- Agents dermatologiques
- Agents antibactériens
- Antibiotiques, Antinéoplasiques
- Agents antifongiques
- Agents antituberculeux
- Antibiotiques, Antituberculeux
- Inhibiteurs de la calcineurine
- Fludarabine
- Phosphate de fludarabine
- Acide mycophénolique
- Ciclosporine
- Cyclosporines
Autres numéros d'identification d'étude
- 1813.00 (Autre identifiant: Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium)
- P30CA015704 (Subvention/contrat des NIH des États-Unis)
- P01CA078902 (Subvention/contrat des NIH des États-Unis)
- NCI-2009-01532 (Identificateur de registre: CTRP (Clinical Trial Reporting Program))
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .
Essais cliniques sur Mycophénolate mofétil
-
University Hospital FreiburgHoffmann-La RocheComplétéUn essai prospectif randomisé sur le mycophénolate mofétil dans la kératoplastie pénétrante à risqueGreffe de cornéeAllemagne
-
Fondo Nacional de Desarrollo Científico y Tecnológico...Complété
-
Fred Hutchinson Cancer CenterUniversity of WashingtonComplétéInfection par le virus de l'immunodéficience humaine IÉtats-Unis
-
Colorado Blood Cancer InstituteInconnueMaladie du greffon contre l'hôteÉtats-Unis
-
Tongji HospitalWuhan Central Hospital; Wuhan Hospital of Traditional Chinese MedicineRecrutement
-
Oslo University HospitalActif, ne recrute pasGreffe du rein; Complications | Suppression immunitaireNorvège
-
University of MinnesotaWyeth is now a wholly owned subsidiary of Pfizer; Roche Pharma AG; Genzyme,...ComplétéEffets secondaires CNIÉtats-Unis